Subjects Screened  
N = 3609

Screening Failures, n=1340 (37%)  
Major Reasons:
- sUA < 8.0 mg/dL at Baseline: 54%
- Withdrew Consent: 10%
- Significant Medical Condition: 6%

Subjects Randomized  
N = 2269

Subjects Receiving Medication  
N = 2269

1 subject with sUA < 8.0 mg/dL was not included in the efficacy analyses

Modified ITT Population  
N = 2268

Febuxostat  
40 mg daily  
N=757

Discontinued  
n=125
Completed  
n=632

Reasons for Discontinuation
- Adverse events: n=49
- Protocol violation: n=10
- Personal reason(s): n=12
- Loss to follow up: n=28
- Therapeutic failure: n=1
- Withdrew consent: n=14
- Did not meet inclusion/exclusion criteria: n=0
- Gout Flare: n=3
- Other: n=8

Febuxostat  
80 mg daily  
N=756

Discontinued  
n=158
Completed  
n=598

Reasons for Discontinuation
- Adverse events: n=61
- Protocol violation: n=2
- Personal reason(s): n=24
- Loss to follow up: n=33
- Therapeutic failure: n=1
- Withdrew consent: n=20
- Did not meet inclusion/exclusion criteria: n=2
- Gout Flare: n=7
- Other: n=8

Allopurinol  
200/300 mg daily  
N=755

Discontinued  
n=135
Completed  
n=620

Reasons for Discontinuation
- Adverse events: n=64
- Protocol violation: n=4
- Personal reason(s): n=9
- Loss to follow up: n=28
- Therapeutic failure: n=1
- Withdrew consent: n=16
- Did not meet inclusion/exclusion criteria: n=0
- Gout Flare: n=2
- Other: n=11